1
|
Khelef K, Maubec E, Jeudy G, Bonniaud B, Pham-Ledard A, Herms F, Aubin F, Beneton N, Dinulescu M, Jannic A, Duval-Modeste A, Archier E, Berthin C, Grange F, Arnault J, Heidelberger V, Moncourier M, Mansard S, Brunet-Possenti F, Triller R, Pracht M, Dumas M, Lauche O, Mortier L, Bedane C, Dalac Rat S. Duration of treatment with cemiplimab in advanced cutaneous squamous cell carcinoma in complete response: Real-life study. J Eur Acad Dermatol Venereol 2024; 38:e71-e73. [PMID: 37595320 DOI: 10.1111/jdv.19435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2023] [Accepted: 08/11/2023] [Indexed: 08/20/2023]
Affiliation(s)
- K Khelef
- Service de Dermatologie, Centre Hospitalier Universitaire (CHU), Dijon, France
| | - E Maubec
- Service de Dermatologie, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (APHP), Bobigny, France
- Campus de Bobigny-Université Sorbonne Paris Nord, Bobigny, France
- UMR 1124, Campus Saint Germain des Prés, Paris, France
| | - G Jeudy
- Service de Dermatologie, Centre Hospitalier Universitaire (CHU), Dijon, France
| | - B Bonniaud
- Service de Dermatologie, Centre Hospitalier Universitaire (CHU), Dijon, France
| | - A Pham-Ledard
- Service de Dermatologie, CHU de Bordeaux, Bordeaux, France
- Université de Bordeaux, Bordeaux, France
| | - F Herms
- Service de Dermatologie, Hôpital Saint-Louis, APHP, Paris, France
| | - F Aubin
- Service de Dermatologie, INSERM 1098, CHU de Besançon de Franche Comté, Besançon, France
- Université de Bourgogne-Franche-Comté, Besançon, France
| | - N Beneton
- Service de Dermatologie, CH du Mans, Le Mans, France
| | - M Dinulescu
- Service de Dermatologie, Hôpital Pontchaillou, Rennes, France
| | - A Jannic
- Service de Dermatologie, Hôpital Henri-Mondor, APHP, Créteil, France
| | - A Duval-Modeste
- Service de Dermatologie, Hôpital Charles-Nicolle, Rouen, France
| | - E Archier
- Service de Dermatologie, Hôpital Saint-Joseph, Marseille, France
| | - C Berthin
- Service de Dermatologie, CHU d'Angers, Angers, France
| | - F Grange
- Service de Dermatologie, CHU de Reims, Reims, France
| | - J Arnault
- Service de Dermatologie, CHU Amiens-Picardie, Amiens, France
| | - V Heidelberger
- Service de Dermatologie, CH Robert-Ballanger, Aulnay-sous-Bois, France
| | - M Moncourier
- Service de Dermatologie, CHU de Grenoble-Alpes, Grenoble, France
| | - S Mansard
- Service de Dermatologie, CHU de Clermont-Ferrand, Clermont-Ferrand, France
| | | | - R Triller
- Service de Dermatologie, Institut Franco-Britannique, Levallois-Perret, France
| | - M Pracht
- Groupe Hospitalier de St-Malo, Saint-Malo, France
| | - M Dumas
- Service de Dermatologie, CH René-Dubos, Pontoise, France
| | - O Lauche
- Clinique Clémentville, Montpellier, France
| | - L Mortier
- Service de Dermatologie, CHU de Lille, Lille, France
- INSERM U 1189, Université de Lille, Lille, France
| | - C Bedane
- Service de Dermatologie, Centre Hospitalier Universitaire (CHU), Dijon, France
| | - S Dalac Rat
- Service de Dermatologie, Centre Hospitalier Universitaire (CHU), Dijon, France
| |
Collapse
|
2
|
Daude M, Dinulescu M, Nguyen JM, Maillard H, Le Duff F, Machet L, Beylot-Barry M, Legoupil D, Wierzbicka-Hainaut E, Bedane C, Leccia MT, Debarbieux S, Meyer N, Monestier S, Bens G, Denis MG, Bossard C, Vergier B, Khammari A, Dréno B. Efficacy of imiquimod in the management of lentigo maligna. J Eur Acad Dermatol Venereol 2023; 37:1785-1791. [PMID: 37114291 DOI: 10.1111/jdv.19141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2022] [Accepted: 04/07/2023] [Indexed: 04/29/2023]
Abstract
BACKGROUND Lentigo maligna (LM) is a melanocytic proliferation occurring on photo-exposed skin that may progress to LM melanoma. Surgery is recommended as first-line treatment. Excision margins of 5-10 mm remain, without international consensus. Several studies have shown that imiquimod, an immunomodulator, induces LM regression. This study investigated the effect of imiquimod versus placebo in neoadjuvant settings. PATIENTS AND METHODS We performed a prospective, randomized, multicentre, phase III clinical study. Patients were randomly assigned in 1:1 ratio to receive imiquimod or placebo for 4 weeks, followed by LM excision 4 weeks after the last application of imiquimod or placebo. The primary endpoint was extra-lesional excision, with a 5 mm margin from the residual pigmentation after imiquimod or vehicle. Secondary endpoints included the gain on the surface removed between the two groups; number of revision surgeries to obtain extra-lesional excisions; relapse-free time; and number of complete remissions after treatment. RESULTS A total of 283 patients participated in this study; 247 patients, 121 patients in the placebo group and 126 in the imiquimod group, accounted for the modified ITT population. The first extralesional extirpation was performed in 116 (92%) imiquimod patients and in 102 (84%) placebo patients; the difference was not significant (p = 0.0743). Regarding the surface of LM, imiquimod reduced the LM surface (4.6-3.1 cm2 ) significantly (p < 0.001) more compared to the placebo (3.9-4.1 cm2 ). CONCLUSION Imiquimod reduces the lentigo maligna surface after 1 month of treatment, without a higher risk of intralesional excision and with a positive aesthetic outcome.
Collapse
Affiliation(s)
- Marie Daude
- Nantes Université, INSERM, CNRS, CHU Nantes, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302/EMR6001, Nantes, France
| | | | - Jean-Michel Nguyen
- Biostatistics and Epidemiology, Hôpital Saint Jacques - CHU Nantes, Nantes, France
| | | | - Florence Le Duff
- Department of Dermatology, CHU Nice, Centre de recherche Clinique, Nice, France
| | | | | | | | | | | | | | - Sébastien Debarbieux
- Department of Dermatology, Hospices Civiles de Lyon, Hôpital Lyon Sud, Pierre Bénite, France
| | - Nicolas Meyer
- Department of Dermatology, CHU Toulouse, Toulouse, France
| | | | - Guido Bens
- Department of Dermatology, CHU Orléans, Orléans, France
| | - Marc G Denis
- Nantes Université, INSERM, CNRS, CHU Nantes, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302/EMR6001, Nantes, France
| | | | | | - Amir Khammari
- Department of Dermatology, Nantes Université, Univ Angers, CHU Nantes, CIC 1413, INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302, Nantes, France
| | - Brigitte Dréno
- Nantes Université, INSERM, CNRS, CHU Nantes, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302/EMR6001, Nantes, France
| |
Collapse
|
3
|
Moghadam P, Tancrede E, Bouaziz JD, Kallout J, Bedane C, Begon E, Bourgault-Villada I, Calugareanu A, Dereure O, Jendoubi F, Pham-Ledard A, Ingen-Housz-Oro S, Picard-Dahan C, Viguier M, Mahevas T, Jachiet M, Charvet E, Cassius C, Alexandre M, Lepelletier C. Efficacity and safety of dupilumab in bullous pemphigoid: a retrospective multicentric study of 36 patients. Br J Dermatol 2023:7157001. [PMID: 37155583 DOI: 10.1093/bjd/ljad136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2023] [Revised: 03/30/2023] [Accepted: 04/25/2023] [Indexed: 05/10/2023]
Abstract
Bullous pemphigoid (BP) is the most common auto immune blistering disease in Europe and its treatment can be challenging. Several published cases reported dupilumab efficiency in refractory patients. We conducted a retrospective multicentric study including 36 patients to evaluate real-life efficiency of dupilumab in BP. Our results suggest that dupilumab in association with high potency topical steroids could be rapidly effective in various clinical forms of BP and seems to be well tolerated in elderly population.
Collapse
Affiliation(s)
- Parna Moghadam
- Dermatology Department, Saint-Louis Hospital, Paris, France
| | | | | | | | | | - Edouard Begon
- Dermatology Department, René Dubos Hospital, Pontoise, France
| | | | | | | | | | | | - Saskia Ingen-Housz-Oro
- Dermatology Department, Henri Mondor Hospital, Univ Paris Est Créteil EpidermE, Créteil, France
| | | | - Manuelle Viguier
- Dermatology Department, National Reference Center for Auto-immune Blistering Diseases, Robert Debré Hospital, Université Reims-Champagne Ardenne, EA 7509 IRMAIC, Reims, France
| | | | - Marie Jachiet
- Dermatology Department, Saint-Louis Hospital, Paris, France
| | | | | | | | | |
Collapse
|
4
|
Cordel N, Flament J, Jouen F, Seta V, Tancrède-Bohin E, Dahan CP, Konstantinou MP, Dereure O, Quéreux G, Prost C, Bedane C, Debarbieux S, Lacour JP, Dompmartin A, Wierzbicka-Hainaut E, Villada IB, Oro SIH, Vabres P, Richard MA, Delaporte E, Pham-Ledard A, Leccia MT, Litrowski N, Michel C, Lagrange B, D'Incan M, Abasq C, Duvert-Lehembre S, Dupuy A, Alcaraz I, Breton-Guitarian AL, Lombart F, Estève E, Machet L, Del Giudice P, Fenot M, Belmondo T, Morin F, Guérin O, Benichou J, Tressières B, Joly P. Anti-BP180 IgG antibody ELISA values correlate with adverse pregnancy outcomes in pemphigoid gestationis. J Eur Acad Dermatol Venereol 2023; 37:1207-1214. [PMID: 36802102 DOI: 10.1111/jdv.18973] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2022] [Accepted: 01/27/2023] [Indexed: 02/20/2023]
Abstract
BACKGROUND Adverse pregnancy outcomes (APO) occur in 35% of patients with pemphigoid gestationis (PG). No biological predictor of APO has been established yet. OBJECTIVES To assess a potential relationship between the occurrence of APO and the serum value of anti-BP180 antibodies at the time of PG diagnosis. METHODS Multicentre retrospective study conducted from January 2009 to December 2019 in 35 secondary and tertiary care centres. INCLUSION CRITERIA (i) diagnosis of PG according to clinical, histological and immunological criteria, (ii) ELISA measurement of anti-BP180 IgG antibodies determined at the time of PG diagnosis with the same commercial kit and (iii) obstetrical data available. RESULTS Of the 95 patients with PG included, 42 had one or more APO, which mainly corresponded to preterm birth (n = 26), intrauterine growth restriction (IUGR) (n = 18) and small weight for gestational age at birth (n = 16). From a ROC curve, we identified a threshold of 150 IU ELISA value as the most discriminating to differentiate between patients with or without IUGR, with 78% sensitivity, 55% specificity, 30% positive and 91% negative predictive value. The threshold >150 IU was confirmed using a cross-validation based on bootstrap resampling, which showed that the median threshold was 159 IU. Upon adjusting for oral corticosteroid intake and main clinical predictors of APO, an ELISA value of >150 IU was associated with the occurrence of IUGR (OR = 5.11; 95% CI: 1.48-22.30; p = 0.016) but not with any other APO. The combination of blisters and ELISA values higher than 150 IU led to a 2.4-fold higher risk of all-cause APO (OR: 10.90; 95% CI: 2.33-82.3) relative to patients with blisters but lower values of anti-BP180 antibodies (OR of 4.54; 95% CI 0.92-34.2). CONCLUSION These findings suggest that anti-BP180 antibody ELISA value in combination with clinical markers is helpful in managing the risk of APO, in particular IUGR, in patients with PG.
Collapse
Affiliation(s)
- Nadège Cordel
- Department of Dermatology and Clinical Immunology, Guadeloupe University Hospital, Pointe-à-Pitre, Guadeloupe.,Univ Rouen Normandie, FOCIS Center of Excellence PAn'THER, Rouen, France
| | - Jasmine Flament
- Department of Dermatology, Rouen University Hospital, Rouen, France
| | - Fabienne Jouen
- Univ Rouen Normandie, FOCIS Center of Excellence PAn'THER, Rouen, France.,Department of Immunology and biotherapies, Rouen University Hospital, Rouen, France
| | - Vannina Seta
- Department of Dermatology, Cochin Hospital AP-HP, Paris, France
| | | | | | | | - Olivier Dereure
- Department of Dermatology, Saint-Eloi University Hospital, Montpellier, France
| | - Gaëlle Quéreux
- Department of Dermatology, Nantes University Hospital, Nantes, France
| | - Catherine Prost
- Department of Dermatology, Avicenne Hospital AP-HP, Bobigny, France
| | - Christophe Bedane
- Department of Dermatology, Limoges University Hospital, Limoges, France
| | | | | | - Anne Dompmartin
- Department of Dermatology, Caen University Hospital, Caen, France
| | | | | | - Saskia Ingen Housz Oro
- Department of Dermatology, Henri Mondor Hospital, AP-HP and Univ Paris Est Créteil, EpidermE, Créteil, France
| | - Pierre Vabres
- Department of Dermatology, Dijon University Hospital, Dijon, France
| | - Marie-Aleth Richard
- Department of Dermatology, La Timone University Hospital APHM, Marseille, France
| | - Emmanuel Delaporte
- Department of Dermatology, UMR 7268 and North University Hospital APHM, Marseille, France
| | - Anne Pham-Ledard
- Department of Dermatology, University Hospital of Bordeaux, Saint-André Hospital, Bordeaux, France
| | - Marie-Thérèse Leccia
- Department of Dermatology, Allergology and Photobiology, Grenoble University Hospital, Grenoble, France
| | - Noémie Litrowski
- Department of Dermatology, Monod General Hospital, Le Havre, France
| | - Catherine Michel
- Department of Dermatology, Emile Muller Hospital, Mulhouse, France
| | | | - Michel D'Incan
- Department of Dermatology, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
| | - Claire Abasq
- Department of Dermatology, Brest University Hospital, Brest, France
| | | | - Alain Dupuy
- Department of Dermatology, Rennes University Hospital, Rennes, France
| | - Isabelle Alcaraz
- Department of Infectious diseases and Travel, Gustave Dron Hospital, Tourcoing, France
| | | | - Florian Lombart
- Department of Dermatology, Amiens University Hospital, Amiens, France
| | - Eric Estève
- Department of Dermatology, Orléans Regional Hospital, Orléans, France
| | - Laurent Machet
- Department of Dermatology, Tours University Hospital, Tours, France
| | - Pascal Del Giudice
- Infectiology-Dermatology Unit, Intercommunal Hospital of Fréjus Saint Raphaël, Fréjus, France
| | - Marion Fenot
- Department of Dermatology, Departmental Hospital of Vendée, La Roche-sur-Yon, France
| | - Thibaut Belmondo
- Department of Immunology, Henri Mondor Hospital, AP-HP, Créteil, France
| | - Florence Morin
- Department of Immunology, Saint-Louis Hospital AP-HP, Paris, France
| | - Olivia Guérin
- Department of Biostatistics, Rouen University Hospital
| | - Jacques Benichou
- Department of Biostatistics, Rouen University Hospital.,Univ Rouen Normandie, IRIB, Inserm U1219, Rouen, France
| | - Benoît Tressières
- Centre d'Investigation Clinique Antilles Guyane, INSERM CIC 1424, Pointe-à-Pitre, Guadeloupe
| | - Pascal Joly
- Univ Rouen Normandie, FOCIS Center of Excellence PAn'THER, Rouen, France.,Department of Dermatology, Rouen University Hospital, Rouen, France
| | | |
Collapse
|
5
|
Dutriaux C, Robert C, Grob JJ, Mortier L, Dereure O, Lebbe C, Mansard S, Grange F, Neidhardt EM, Lesimple T, Machet L, Bedane C, Maillard H, Dalac-Rat S, Nardin C, Szenik A, Denden A, Saiag P. An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases. Eur J Cancer 2022; 175:254-262. [PMID: 36170791 DOI: 10.1016/j.ejca.2022.07.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2022] [Revised: 07/06/2022] [Accepted: 07/20/2022] [Indexed: 11/03/2022]
Abstract
BACKGROUND Despite the poor prognosis associated with melanoma brain metastases (BM), data concerning these patients and their inclusion in clinical trials remains scarce. We report here the efficacy results of a subgroup analysis in patients with BRAFV600-mutant melanoma and BM treated with BRAF and MEK inhibitors dabrafenib (D) and trametinib (T). PATIENTS AND METHODS This phase IIIb single-arm, open-label, multicenter, French study included patients with unresectable stage IIIc or IV BRAFV600-mutant melanoma with or without BM. The present analysis focuses on patients with BM. Response rates were determined clinically and/or radiologically as per standard clinical practice. Progression-free survival (PFS) was estimated using the Kaplan Meier analysis and modelled with multivariate Cox regression model. Risk subgroups were identified using an exponential regression tree analysis. Significance was set at p < 0.05. RESULTS Between March 2015 and November 2016, 856 patients were included and 275 (32%) patients had BM. Median PFS was 5.68 months (95% confidence interval [CI], 5.29-6.87). Significant independent factors associated with shorter PFS were ECOG ≥1, elevated serum lactate dehydrogenase (LDH), ≥3 metastatic sites, and non-naïve status. The binary-split classification and regression tree modelling identified baseline LDH and ECOG status as major prognostic factors. CONCLUSION This is to date the largest, close to real-world, study in advanced BRAFV600-mutant melanoma patients with BM treated with D+T. ECOG >1, ≥3 metastatic sites and elevated LDH were associated with shorter PFS, a finding previously demonstrated only in patients without BM. Further studies are warranted to determine the optimal treatment sequence in this population.
Collapse
Affiliation(s)
- Caroline Dutriaux
- Department of Dermatology, CHU Bordeaux Hôpital St. André, Bordeaux, France.
| | - Caroline Robert
- Department of Dermatology, Institut Gustave Roussy, Villejuif, France
| | - Jean-Jacques Grob
- Department of Dermatology, Aix Marseille University, and APHM University Hospital Timone, Marseille, France
| | - Laurent Mortier
- Department of Dermatology, Hopital Claude Huriez, Lille, France
| | - Olivier Dereure
- Department of Dermatology, CHU Montpellier, Montpellier, France
| | - Céleste Lebbe
- Université de Paris, INSERM U976, Team 1, HIPI, F-75010, Paris, France; AP-HP Hôpital Saint Louis, Service de Dermatologie, F-75010, Paris, France
| | - Sandrine Mansard
- Department of Dermatology, CHU Estaing, Clermont-Ferrand, France
| | | | | | - Thierry Lesimple
- Department of Medical Oncology, Eugene Marquis Center, Rennes, France
| | - Laurent Machet
- Department of Dermatology, CHRU de Tours et Université François Rabelais de Tours, Tours, France
| | | | | | | | - Charlée Nardin
- Dermatology, CHU de Besançon, INSERM U-1098, University of Besançon, Besançon, France
| | - Alexandra Szenik
- Department of Medical Oncology, Novartis Pharma S.A.S., Rueil-Malmaison, France
| | - Amine Denden
- Department of Medical Oncology, Novartis Pharma S.A.S., Rueil-Malmaison, France
| | - Philippe Saiag
- Department of Dermatology, AP-HP, & EA 4340, University UVSQ, University Paris-Saclay, Boulogne-Billancourt, France
| |
Collapse
|
6
|
Barranca A, Debarbieux S, Tancrede-Bohin E, Saillard C, Sassolas B, Voisin S, Fortenfant F, Bost C, Claeyssens-Donadel S, Joly P, Bedane C, Bulai-Livideanu C, Paul C, Konstantinou MP. A nationwide study evaluating the association of autoimmune bullous diseases and acquired haemophilia: description of clinical and prognostic features. Br J Dermatol 2021; 186:899-902. [PMID: 34921677 DOI: 10.1111/bjd.20953] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2021] [Revised: 10/07/2021] [Accepted: 12/07/2021] [Indexed: 11/28/2022]
Affiliation(s)
- Alexis Barranca
- Dermatology Department, Paul Sabatier University, University Hospital of Toulouse, Toulouse, France
| | | | - Emmanuelle Tancrede-Bohin
- Dermatology Department, Saint Louis University Hospital, Assistance Publique Hôpitaux de Paris, Paris, France
| | - Clemence Saillard
- Dermatology Department, University Hospital of Rennes, Rennes, France
| | - Bruno Sassolas
- Dermatology Department, University Hospital of Brest, Brest, France
| | - Sophie Voisin
- Hématology Department, University Hospital of Toulouse, Toulouse, France
| | | | - Chloe Bost
- Immunology Department, University Hospital of Toulouse, Toulouse, France
| | | | - Pascal Joly
- Dermatology Department, University Hospital of Rouen, Rouen, France
| | - Christophe Bedane
- Dermatology Department, University Hospital of Limoges, Limoges, France
| | - Cristina Bulai-Livideanu
- Dermatology Department, Paul Sabatier University, University Hospital of Toulouse, Toulouse, France
| | - Carle Paul
- Dermatology Department, Paul Sabatier University, University Hospital of Toulouse, Toulouse, France
| | | |
Collapse
|
7
|
Touhouche TA, Tournier E, Lamant L, Hardy J, Taieb A, Labreze C, Cony M, Lepreux S, Chiaverini C, Lacour JP, Cardot-Leccia N, Bedane C, Assikar S, Charissoux A, Mazereeuw-Hautier J. Annular lipoatrophy of the ankle: Four new pediatric cases and a review of the literature. Pediatr Dermatol 2021; 38:1292-1297. [PMID: 34418138 DOI: 10.1111/pde.14670] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Annular lipoatrophy of the ankle is a rare and unique acquired lipoatrophic panniculitis that mainly affects children. There is no consensus on treatment, and the long-term course is not well known. We present four new pediatric cases that contribute to the understanding of this rare disease.
Collapse
Affiliation(s)
- Timila Assia Touhouche
- University Hospital, Larrey Hospital, Dermatology Department, Paul Sabatier University, Reference Centre for Rare Skin Diseases Toulouse, Toulouse, France
| | - Emilie Tournier
- Department of Pathology, University Cancer Institute, Oncopole, Toulouse, France
| | - Laurence Lamant
- Department of Pathology, University Cancer Institute, Oncopole, Toulouse, France
| | - Juliette Hardy
- University Hospital, Larrey Hospital, Dermatology Department, Paul Sabatier University, Reference Centre for Rare Skin Diseases Toulouse, Toulouse, France
| | - Alain Taieb
- University Hospital Center, Dermatology Department, Reference Centre for Rare Skin Diseases, Bordeaux, France
| | - Christine Labreze
- University Hospital Center, Dermatology Department, Reference Centre for Rare Skin Diseases, Bordeaux, France
| | - Marianne Cony
- University Hospital Center, Dermatology Department, Reference Centre for Rare Skin Diseases, Bordeaux, France
| | - Sebastien Lepreux
- Department of Pathology, University Hospital Center, Bordeaux, France
| | - Christine Chiaverini
- University Hospital Center, Dermatology Department, Reference Centre for Rare Skin Diseases, Nice, France
| | - Jean Philippe Lacour
- University Hospital Center, Dermatology Department, Reference Centre for Rare Skin Diseases, Nice, France
| | | | - Christophe Bedane
- Department of Dermatology, Dupuytren Hospital, University Hospital Center, Limoges, France
| | - Safae Assikar
- Department of Dermatology, Dupuytren Hospital, University Hospital Center, Limoges, France
| | - Aurélie Charissoux
- Department of Dermatology, Dupuytren Hospital, University Hospital Center, Limoges, France
| | - Juliette Mazereeuw-Hautier
- University Hospital, Larrey Hospital, Dermatology Department, Paul Sabatier University, Reference Centre for Rare Skin Diseases Toulouse, Toulouse, France
| |
Collapse
|
8
|
Hébert V, Bastos S, Drenovska K, Meijer J, Ingen-Housz-Oro S, Bedane C, Lunardon L, Debarbieux S, Jedlickova H, Caux F, Chaby G, D'Incan M, Feliciani C, Boulard C, Schumacher N, Schmidt E, Roussel A, Richard MA, Gottlieb J, Ferranti V, Guérin O, Bénichou J, Joly P. International multicentre observational study to assess the efficacy and safety of a 0·5 mg kg -1 per day starting dose of oral corticosteroids to treat bullous pemphigoid. Br J Dermatol 2021; 185:1232-1239. [PMID: 34173243 DOI: 10.1111/bjd.20593] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/17/2021] [Indexed: 11/28/2022]
Abstract
BACKGROUND European guidelines propose a 0·5 mg kg-1 per day dose of oral prednisone as initial treatment for bullous pemphigoid (BP). We assessed the safety and efficacy of this regimen depending on BP extent and general condition of the patients. METHODS In a prospective international study, we consecutively included all patients diagnosed with BP. Patients received a 0·5 mg kg-1 per day dose of prednisone, which was then gradually tapered 15 days after disease control, with the aim of stopping prednisone or maintaining minimal treatment (0·1 mg kg-1 per day) within 6 months after the start of treatment. The two coprimary endpoints were control of disease activity at day 21 and 1-year overall survival. Disease severity was assessed according to the Bullous Pemphigoid Disease Area Index (BPDAI) score. RESULTS In total, 198 patients were included between 2015 and 2017. The final analysis comprised 190 patients with a mean age of 80·9 (SD 9·1) years. Control of disease activity was achieved at day 21 in 119 patients [62·6%, 95% confidence interval (CI) 55·3-69.5]; 18 of 24 patients (75%, 95% CI 53·3-90·2), 75 of 110 patients (68·8%, 95% CI 59·2-77·3) and 26 of 56 patients (46.4%, 95% CI 33·0-60·3) had mild, moderate and severe BP, respectively (P = 0·0218). A total of 30 patients died during the study. The overall Kaplan-Meier 1-year survival was 82·6% (95% CI 76·3-87·4) corresponding to 90·9%, 83·0% and 80·0% rates in patients with mild, moderate and severe BP, respectively (P = 0·5). Thresholds of 49 points for BPDAI score and 70 points for Karnofsky score yielded maximal Youden index values with respect to disease control at day 21 and 1-year survival, respectively. CONCLUSIONS A 0·5 mg kg-1 per day dose of prednisone is a valuable therapeutic option in patients with mild or moderate BP whose general condition allows them to be autonomous.
Collapse
Affiliation(s)
- V Hébert
- Department of Dermatology, Rouen University Hospital, Center for Autoimmune Bullous Diseases, and INSERM U1234, Normandie University, Rouen, France
| | - S Bastos
- Department of Dermatology, Rouen University Hospital, Center for Autoimmune Bullous Diseases, and INSERM U1234, Normandie University, Rouen, France
| | - K Drenovska
- Department of Dermatology, Medical University of Sofia, Sofia, Bulgaria
| | - J Meijer
- Center for Blistering Diseases, Department of Dermatology, University Medical Center Groningen, Groningen, the Netherlands
| | - S Ingen-Housz-Oro
- Department of Dermatology, Henri Mondor University Hospital, (AP-HP), Creteil, France
| | - C Bedane
- Department of Dermatology, Limoges University Hospital, Limoges, France
| | - L Lunardon
- Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - S Debarbieux
- Department of Dermatology, Hospices Civils de Lyon, Lyon, France
| | - H Jedlickova
- Department of Dermatology, St. Anne's Faculty Hospital, Brno, Czech Republic
| | - F Caux
- Department of Dermatology, Avicenne Hospital, University Paris 13, Bobigny, France
| | - G Chaby
- Department of Dermatology, Amiens University Hospital, Amiens, France
| | - M D'Incan
- Department of Dermatology, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
| | - C Feliciani
- Section of Dermatology, Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy
| | - C Boulard
- Department of Dermatology, Monod General Hospital, le Havre, France
| | - N Schumacher
- Department of Dermatology, University of Lübeck, Lübeck, Germany
| | - E Schmidt
- Department of Dermatology, University of Lübeck, Lübeck, Germany.,Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany
| | - A Roussel
- Department of Dermatology, Orleans Hospital, Orléans, France
| | - M A Richard
- Department of Dermatology, Hôpital la Timone, Assistance Publique des Hôpitaux de Marseille, Marseille, France
| | - J Gottlieb
- Department of Dermatology, Saint Louis Hospital, (AP-HP), Paris, France
| | - V Ferranti
- Department of Biostatistics, Rouen University Hospital, Rouen, France
| | - O Guérin
- Department of Biostatistics, Rouen University Hospital, Rouen, France
| | - J Bénichou
- Department of Biostatistics, Rouen University Hospital, Rouen, France
| | - P Joly
- Department of Dermatology, Rouen University Hospital, Center for Autoimmune Bullous Diseases, and INSERM U1234, Normandie University, Rouen, France
| | | |
Collapse
|
9
|
Marescassier H, Dousset L, Beylot-Barry M, Célérier P, Vaillant L, Bedane C, Leclère F, Wierzbicka-Hainaut E, Masson Regnault M. Predictive Factors of Non-Response to Vismodegib in Locally Advanced Basal-Cell Carcinoma. Dermatology 2021; 237:1023-1028. [PMID: 33472195 DOI: 10.1159/000512889] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2020] [Accepted: 11/08/2020] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Vismodegib has shown clinical efficacy in the management of locally advanced basal cell carcinomas (laBCC). However, non-response to vismodegib is observed in 2-13.5% of patients in clinical studies. The purpose of this study was to identify factors associated with non-response to vismodegib in patients with laBCC. METHODS We carried out a retrospective multicenter study, including patients with laBCC treated with vismodegib, from July 2011 to May 2019. Response to treatment was assessed according to the RECIST 1.1 criteria. Patients were categorized as responders with a complete response or a partial response or non-responders with a stable disease or a progressive disease according to what has been observed during follow-up. Patient demographics, tumor profile, and treatment modalities were compared in responders and non-responders. RESULTS Eighty-three patients with laBCC were included in the study. Twenty-five (30.1%) were non-responders to vismodegib. History of treatment with radiotherapy, presence of muscle involvement and intermittent treatment with vismodegib were significantly associated with a non-response (p < 0.001, p = 0.025, p < 0.001). Bone involvement (p = 0.2) and morpheaform IaBCC subtype (p = 0.056) were more frequent in non-responders without reaching statistical significance. CONCLUSION In this study, non-response of laBCC to vismodegib therapy was associated with muscle involvement. Previous radiotherapy and intermittent use of vismodegib have been identified as causes favoring non-response to vismodegib. Due to the low numbers of patients included in the study, it is difficult to draw firm conclusions. Further studies are needed to confirm these data.
Collapse
Affiliation(s)
| | - Léa Dousset
- Department of Dermatology, CHU Bordeaux, Bordeaux, France
| | | | | | | | | | - Franck Leclère
- Department of Plastic Surgery, CHU Poitiers, Poitiers, France
| | - Ewa Wierzbicka-Hainaut
- Department of Dermatology, CHU Poitiers, Poitiers, France.,Laboratoire Inflammation, Tissus Epithéliaux et Cytokines (LITEC), EA4331, Université de Poitiers, Poitiers, France
| | - Marie Masson Regnault
- Department of Dermatology, CHU Poitiers, Poitiers, France, .,Laboratoire Inflammation, Tissus Epithéliaux et Cytokines (LITEC), EA4331, Université de Poitiers, Poitiers, France,
| |
Collapse
|
10
|
Fredeau L, Hober C, Pham-Ledard A, Boubaya M, Herms F, Celerier P, Aubin F, Beneton N, Dinulescu M, Jannic A, Meyer N, Duval Modeste AB, Cesaire L, Neidhardt EM, Archier E, Dreno B, Lesage C, Berthin C, Kramkimel N, Grange F, De Quatrebarbes J, Stoebner P, Poulalhon N, Arnault J, Abed S, Bonniaud B, Darras S, Heidelberger V, Devaux S, Moncourier M, Misery L, Mansard S, Etienne M, Brunet-Possenti F, Jacobzone C, Lesbazeilles R, Skowron F, Sanchez J, Catala S, Samimi M, Tazi Y, Spaeth D, Gaudy-Marqueste C, Collard O, Triller R, Pracht M, Dumas M, Peuvrel L, Combe P, Lauche O, Guillet P, Reguerre Y, Kupfer-Bessaguet I, Solub D, Schoeffler A, Bedane C, Dalac S, Mortier L, Maubec E. Cémiplimab et carcinomes épidermoïdes cutanés localement évolués ou métastatiques : premières données de vie réelle. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
11
|
Mio Bertolo E, Assikar S, Hazard M, Matei I, Bedane C. Photothérapie dynamique en lumière naturelle associée au mébutate d’ingénol dans le traitement des kératoses actiniques : étude pilote comparative. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.217] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
12
|
Khammari A, Dinulescu M, Nguyen JM, Cassecuel J, Maillard H, Le Duff F, Machet L, Beylot-Barry M, Legoupil D, Wierzbicka-Hainaut E, Bedane C, Leccia MT, Debarbieux S, Meyer N, Monestier S, Bens G, Denis M, Vourch M, Bossard C, Vergier B, Dréno B. L’efficacité de l’imiquimod dans la prise en charge du mélanome de Dubreuilh in situ (lentigo malin). Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
13
|
Marescassier H, Dousset L, Hainaut E, Bedane C, Vaillant L, Celerier P, Beylot-Barry M, Masson Regnault M. Facteurs prédictifs de non réponse au vismodégib dans les carcinomes basocellulaires localement avancés. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
14
|
Flament J, Jouen F, Tancrède-Bohin E, Oro S, Picard-Dahan C, Konstantinou M, Dereure O, Seta V, Quereux G, Prost C, Bedane C, Debarbieux S, Bourgault-Villada I, Delaporte E, Lacour JP, Richard MA, Pham-Ledard A, D’Incan M, Abasq C, Duvert-Lehembre S, Lombart F, Dupuy A, Hainaut E, Dompmartin A, Leccia MT, Vabres P, Alcaraz I, Michel C, Lagrange B, Litrowski N, Estève E, Machet L, Martin L, Del Giudice P, Fenot M, Belmondo T, Morin F, Tressières B, Joly P, Cordel N. Étude du taux d’anticorps anti-BPAG2, mesuré par technique ELISA, comme biomarqueur des complications gravidiques au cours de la pemphigoïde de la grossesse. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
15
|
Dréno B, Dinulescu M, NGuyen JM, Maillard H, Le Duff F, Machet L, Beylot-Barry M, Legoupil D, Wierzbicka-Hainaut E, Bedane C, Leccia MT, Debarbieux S, Meyer N, Monestier S, Bens G, Denis MG, Bossard C, Vergier B, Khammari A. Efficacy of imiquimod in the management of lentigo maligna. J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.15_suppl.10074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10074 Background: Lentigo maligna (LM), a melanocytic proliferation occurring on photoexposed skin, might progress to LM melanoma. Surgery is recommended as first-line treatment. However, the main challenge is the size of the excision inducing often-aesthetic injuries on the face and thus often refused by patients. The excision margins of 5 to 10 mm remain without international consensus. Several studies have shown that imiquimod induced LM regression, acting by enhancing IFN-γ production and effector function of T cells. The main goal of this study is to investigate the effect of imiquimod versus placebo in neoadjuvant setting to decrease the excision size as from the first surgical procedure. Methods: We performed a prospective, randomized, open, multicenter, phase III clinical study (NCT01720407). The health authority and ethics committee approvals were obtained and all subjects signed an informed consent. The primary endpoint was to demonstrate that in neoadjuvant situation, imiquimod could reduce the surgical excision size of LM with a healthy tissue margin of 5 mm. The main inclusion criteria were: Patients > 18 years fit for surgery. LM of the head histologically confirmed and not previously treated. Surface lesion ≥ to 1cm² and ≤ to 20cm². The two treatment arms were imiquimod or placebo followed by LM excision. Imiquimod or placebo were applied once daily, 5 days/week for 4 weeks followed by 5 mm margin surgery performed four weeks after the last treatment application. For sample size, 268 patients were expected to demonstrate a difference of 15% between the two arms in a bilateral situation with an alpha risk of 5% and a beta risk of 20%. Results: The trial involved 273 patients, 238 (105 men (44%) and 133 women (56%), mean age of 71 ± 10.2 years, were analyzed in modified ITT. Statistical analysis was performed on 122 patients in the imiquimod arm and 116 patients in the placebo arm. For the primary endpoint, the first extralesionnal excision has been achieved for 112 (91.8%) patients in the imiquimod arm and for 98 (84.5%) placebo patients group. There was no significant difference (p value = 0.1067) between the two arms. However, regarding the surface of LM, imiquimod allowed a highly significant reduction (4.2 cm² ± 4.6 to 2.3 cm² ± 3.3) compared to LM treated by placebo (4.0 cm² ± 3.5 to 4.0 cm² ±3.3; p < 0.0001). Conclusions: This randomized prospective study shows that imiquimod reduces the LM area (-50%) after one month of treatment. Reducing the surface of LM with imiquimod is not associated with a higher risk of intralesional excision (marge 5mm), with a significant esthetic result (less excised surface). Clinical trial information: NCT01720407.
Collapse
Affiliation(s)
- Brigitte Dréno
- Department of Dermatology-Oncology, Nantes University, CHU Nantes, CIC1413, CRCINA, Nantes, France
| | | | | | | | | | - Laurent Machet
- Dermatology department, CHRU, Inserm U-1253, University of Tours, France, Tours, France
| | - Marie Beylot-Barry
- Dermatology, Hôpital Saint-André, CHU de Bordeaux, Université de Bordeaux, Bordeaux, France
| | | | | | | | - Marie Thérèse Leccia
- Dermatology department, CHU Albert Michalon, Grenoble; Université de Grenoble, Grenoble, France
| | | | | | | | - Guido Bens
- Dermatology department, CHR Orleans., Orleans, France
| | - Marc G. Denis
- Department of Biochemistry, Nantes University Hospital, Nantes, France
| | - Celine Bossard
- Pathology Department, CHU Hotel Dieu and CRCINA, INSERM U1232, Nantes, France
| | - Beatrice Vergier
- CHU Bordeaux-Université Bordeaux, INSERM U1053, Team 3, Bordeaux, France
| | - Amir Khammari
- Dermato-Oncology Department, Nantes University, Nantes, France
| |
Collapse
|
16
|
Chen D, Odueyungbo A, Csinady E, Gearhart L, Lehane P, Cheu M, Maho‐Vaillant M, Prost‐Squarcioni C, Hebert V, Houivet E, Calbo S, Caillot F, Golinski M, Labeille B, Picard‐Dahan C, Paul C, Richard M, Bouaziz J, Duvert‐Lehembre S, Bernard P, Caux F, Alexandre M, Ingen‐Housz‐Oro S, Vabres P, Delaporte E, Quereux G, Dupuy A, Debarbieux S, Avenel‐Audran M, D'Incan M, Bedane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot‐Barry M, Dereure O, Sassolas B, Benichou J, Musette P, Joly P. Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect. Br J Dermatol 2020; 182:1111-1119. [PMID: 31487383 PMCID: PMC7317434 DOI: 10.1111/bjd.18482] [Citation(s) in RCA: 46] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/29/2019] [Indexed: 12/11/2022]
Abstract
BACKGROUND Corticosteroids (CS) with or without adjuvant immunosuppressant agents are standard treatment for pemphigus vulgaris (PV). The efficacy of adjuvant therapies in minimizing steroid-related adverse events (AEs) is unproven. OBJECTIVES To utilize data collected in a French investigator-initiated, phase III, open-label, randomized controlled trial to demonstrate the efficacy and safety of rituximab and seek approval for its use in PV. METHODS This was an independently conducted post hoc analysis of the moderate-to-severe PV subset enrolled in the Ritux 3 study. Patients were randomized to rituximab plus 0·5 or 1·0 mg kg-1 per day prednisone tapered over 3 or 6 months, or 1·0 or 1·5 mg kg-1 per day prednisone alone tapered over 12 or 18 months, respectively (according to disease severity). The primary end point was complete remission at month 24 without CS (CRoff) for ≥ 2 months, and 24-month efficacy and safety results were also reported. RESULTS At month 24, 34 of 38 patients (90%) on rituximab plus prednisone achieved CRoff ≥ 2 months vs. 10 of 36 patients (28%) on prednisone alone. Median total cumulative prednisone dose was 5800 mg in the rituximab plus prednisone arm vs. 20 520 mg for prednisone alone. Eight of 36 patients (22%) who received prednisone alone withdrew from treatment owing to AEs; one rituximab-plus-prednisone patient withdrew due to pregnancy. Overall, 24 of 36 patients (67%) on prednisone alone experienced a grade 3/4 CS-related AE vs. 13 of 38 patients (34%) on rituximab plus prednisone. CONCLUSIONS In patients with moderate-to-severe PV, rituximab plus short-term prednisone was more effective than prednisone alone. Patients treated with rituximab had less CS exposure and were less likely to experience severe or life-threatening CS-related AEs. What's already known about this topic? Pemphigus vulgaris (PV) is the most common type of pemphigus. Corticosteroids, a standard first-line treatment for PV, have significant side-effects. Although their effects are unproven, adjuvant corticosteroid-sparing agents are routinely used to minimize steroid exposure and corticosteroid-related side-effects. There is evidence that the anti-CD20 antibody rituximab is effective in the treatment of patients with severe recalcitrant pemphigus and in patients with newly diagnosed pemphigus. What does this study add? This study provides a more detailed analysis of patients with PV enrolled in an investigator-initiated trial. Rituximab plus prednisone had a steroid-sparing effect and more patients achieved complete remission off prednisone. Fewer patients experienced grade 3 or grade 4 steroid-related adverse events than those on prednisone alone. This collaboration between academia and industry, utilizing independent post hoc analyses, led to regulatory authority approvals of rituximab in moderate-to-severe PV.
Collapse
|
17
|
Meaume S, Thomas P, Truchetet F, Celerier P, Becherel PA, Teot L, Bedane C. Impregnated acetate gauze compared with lipido-colloid contact layer at dressing removal pain: a single-blind cross-over randomised control trial. J Wound Care 2019; 28:89-101. [PMID: 30767647 DOI: 10.12968/jowc.2019.28.2.89] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
OBJECTIVE To evaluate the performance of Jelonet Plus (JP) and UrgoTul (UT), assessing pain at dressing removal when managing acute or chronic wounds at granulation and epithelialisation stages. METHODS This was a randomised, multicentre, controlled single-blinded study using a cross-over design. Hospitalised and ambulatory patients presenting with non-infected acute or chronic wounds (at least 40% of wound area of ≤100cm2 covered with granulation tissue) were randomly allocated to be treated with either JP or UT dressings applied according to a standardised local care procedure for two days. At the following visit, patients received the other dressing for a second 2-day period. Pain was evaluated after two days of dressing application and immediately after its removal using a 100mm Visual Analog Scale (VAS). A pain level >30mm was considered as clinically relevant. A lower limit of -12% was determined as the threshold necessary to demonstrate the non-inferiority of JP compared to UT. RESULTS For the 99 patients completing the study, a difference of 7.9% was observed in favour of JP (83.8% JP versus 75.9% UT) for pain immediately after dressing removal (VAS score < 30mm) with a confidence interval (CI) lower limit of -2.6%, demonstrating non-inferiority (pre-defined limit of -12%). Concerning pain at dressing removal, a difference of 19.6% was observed in favour of JP (81.6% versus 62.0%; p=0.029 for superiority analysis), with a CI lower limit ranging from 2.4% to 38.9%. Therefore, superiority could be concluded. A statistically significant period effect was detected (p=0.003) with fewer patients experiencing pain after the second period day 2 (D2) to day 4 (D4) than the first day 0 (D0) to D2. A statistically significant cross-over effect was also detected (p=0.047), with fewer patients experiencing pain when JP was applied first followed by UT. This suggests a carry-over effect thus preventing a full cross-over design analysis. Adherence of the dressing was less frequent with the JP than the UT dressing (2.0% JP versus 6.9% with UT). CONCLUSION Non-inferiority of pain at dressing removal was demonstrated with JP. Superiority on this criteria was non-significant but we found adherence of the dressing to the wound bed to be more rare.
Collapse
Affiliation(s)
- Sylvie Meaume
- Dermatologist and Geriatrician, Head of Geriatric Department and Wound Care Unit; Rothschild University Hospital, Paris, France
| | | | | | - Philippe Celerier
- Dermatologist and Vascular Surgeon; Centre Hospitalier du Mans, France
| | | | - Luc Teot
- Plastic surgeon; Department of Plastic & Reconstructive Surgery and Wound Healing, Lapeyronie, Montpellier, France
| | - Christophe Bedane
- Dermatologist; Dermatology and out-patients consultations, Hôpital Dupuytren, Limoges, France
| |
Collapse
|
18
|
Berkani N, Joly P, Golinski ML, Colliou N, Lim A, Larbi A, Riou G, Caillot F, Bernard P, Bedane C, Delaporte E, Chaby G, Dompmartin A, Hertl M, Calbo S, Musette P. Author Correction: B-cell depletion induces a shift in self antigen specific B-cell repertoire and cytokine pattern in patients with bullous pemphigoid. Sci Rep 2019; 9:18991. [PMID: 31813939 PMCID: PMC6900399 DOI: 10.1038/s41598-019-54421-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Affiliation(s)
| | - Pascal Joly
- Normandie University, UNIROUEN, INSERM U1234, Rouen, France.,Normandie University, UNIROUEN, Rouen University Hospital, Department of Dermatology, French reference center for autoimmune bullous diseases, F76000, Rouen, France
| | - Marie-Laure Golinski
- Normandie University, UNIROUEN, INSERM U1234, Rouen, France.,Normandie University, UNIROUEN, Rouen University Hospital, Department of Dermatology, French reference center for autoimmune bullous diseases, F76000, Rouen, France
| | | | - Annick Lim
- Immunoscope plateform, Pasteur Institute, Paris, France
| | - Anis Larbi
- Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore
| | - Gaetan Riou
- Normandie University, UNIROUEN, INSERM U1234, Rouen, France
| | | | - Philippe Bernard
- Department of Dermatology, Reims University Hospital, Reims, France
| | - Christophe Bedane
- Department of Dermatology, Limoges University Hospital, Limoges, France
| | | | - Guillaume Chaby
- Department of Dermatology, Amiens University Hospital, Amiens, France
| | - Anne Dompmartin
- Department of Dermatology, Caen University Hospital, Caen, France
| | - Michael Hertl
- Department of Dermatology and Allergology, Philipps University, Marburg, Germany
| | | | - Philippe Musette
- Normandie University, UNIROUEN, Rouen University Hospital, Department of Dermatology, French reference center for autoimmune bullous diseases, F76000, Rouen, France. .,INSERM U976, Saint Louis Hospital, Paris, France.
| |
Collapse
|
19
|
Bastos S, Hebert V, Vassileva S, Patsatsi A, Meijer J, Quéreux G, Bedane C, Prost-Squarcioni C, Debardieux S, Oro S, Chaby G, D’Incan M, Litrowski N, Boulard C, Lunardon L, Kiritsi D, Jedlickova H, Feliciani C, Roussel A, Kottler D, Plantin P, Richard MA, Friedrichsen L, Abasq C, Duvert Lehembre S, Gottlieb J, Zebrowska A, Hofmann S, Joly P. Efficacité et tolérance de la prednisone à 0,5 mg/kg/j en traitement initial de la pemphigoïde bulleuse. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.038] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
20
|
Bourgaux M, Marcaillou M, Matei I, Delaumenie S, Prud'homme R, Souyri N, Bedane C. Man of stone: A case of a chronic actinic dermatitis mimicking a cutis verticis gyrata. J Eur Acad Dermatol Venereol 2019; 34:e129-e130. [PMID: 31715028 DOI: 10.1111/jdv.16068] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- M Bourgaux
- Dermatology Department, CHU Dupuytren, 2 av. Martin Luther King, Limoges, F-87000, France
| | - M Marcaillou
- Dermatology Department, CHU Dupuytren, 2 av. Martin Luther King, Limoges, F-87000, France
| | - I Matei
- Dermatology Department, CHU Dupuytren, 2 av. Martin Luther King, Limoges, F-87000, France
| | - S Delaumenie
- Dermatology Department, CHU Dupuytren, 2 av. Martin Luther King, Limoges, F-87000, France
| | - R Prud'homme
- Dermatology Department, CHU Dupuytren, 2 av. Martin Luther King, Limoges, F-87000, France
| | - N Souyri
- Dermatology Department, CHU Dupuytren, 2 av. Martin Luther King, Limoges, F-87000, France
| | - C Bedane
- Dermatology Department, CHU Dupuytren, 2 av. Martin Luther King, Limoges, F-87000, France
| |
Collapse
|
21
|
Mignard C, Maho-Vaillant M, Prost-Squarcioni C, Calbo S, Golinski ML, Labeille B, Picard-Dahan C, Konstantinou M, Richard MA, Bouaziz J, Duvert-Lehembre S, Bernard P, Caux F, Alexandre M, Oro S, Vabres P, Quereux G, Dupuy A, Debarbieux S, Martin L, D’Incan M, Bedane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Hébert V, Joly P. Facteurs pronostiques de rechute à long terme chez les patients atteints de pemphigus traités par rituximab en première ligne. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
22
|
Saiag P, Robert C, Grob J, Mortier L, Dereure O, Lebbe C, Mansard S, Grange F, Neidhardt EM, Lesimple T, Machet L, Bedane C, Maillard H, Dalac-Rat S, Nardin C, Szenik A, Denden A, Dutriaux C. Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: An open label, non randomized study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz255.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
23
|
Dutriaux C, Robert C, Grob J, Mortier L, Dereure O, Lebbe C, Mansard S, Grange F, Neidhardt EM, Lesimple T, Machet L, Bedane C, Maillard H, Dalac-Rat S, Nardin C, Szenik A, Denden A, Saiag P. An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: A subgroup analysis of patients with brain metastasis. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz255.021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
24
|
Delaumenie S, Assikar S, Prudhomme R, Matei I, Souyri N, Dalmay F, Bedane C. Methotrexate is safe and efficient as long-term treatment for bullous pemphigoid. Eur J Dermatol 2019; 29:217-218. [PMID: 30734720 DOI: 10.1684/ejd.2019.3501] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- Stephanie Delaumenie
- Department of Dermatology and National Reference Center for Bullous Diseases -MALIBUL, 2 Avenue Martin Luther King, Limoges, 87 000, France
| | - Safae Assikar
- Department of Dermatology and National Reference Center for Bullous Diseases -MALIBUL, 2 Avenue Martin Luther King, Limoges, 87 000, France
| | - Romain Prudhomme
- Department of Dermatology and National Reference Center for Bullous Diseases -MALIBUL, 2 Avenue Martin Luther King, Limoges, 87 000, France
| | - Ioana Matei
- Department of Dermatology and National Reference Center for Bullous Diseases -MALIBUL, 2 Avenue Martin Luther King, Limoges, 87 000, France
| | - Nicole Souyri
- Department of Dermatology and National Reference Center for Bullous Diseases -MALIBUL, 2 Avenue Martin Luther King, Limoges, 87 000, France
| | - François Dalmay
- Department of Dermatology and National Reference Center for Bullous Diseases -MALIBUL, 2 Avenue Martin Luther King, Limoges, 87 000, France
| | - Christophe Bedane
- Department of Dermatology and National Reference Center for Bullous Diseases -MALIBUL, 2 Avenue Martin Luther King, Limoges, 87 000, France
| |
Collapse
|
25
|
Jelti L, Prost-Squarcioni C, Ingen-Housz-Oro S, Caux F, Bernard P, Bedane C, Alexandre M, Dereure O, Quereux G, Le Bidre E, Plée J, Picard-Dahan C, Le Roux-Villet C, Duvert-Lehembre S, Richard MA, Delaporte E, Debarbieux S, Jullien D, D'Incan M, Konstantinou MP, Bouaziz JD, Tancrède-Bohin E, Doutre MS, Bourgault Villada I, Cordel N, Sassolas B, Viguier MA, Mellottée B, Jouen F, Hebert V, Joly P. [Update of the French recommendations for the management of pemphigus]. Ann Dermatol Venereol 2019; 146:279-286. [PMID: 30929874 DOI: 10.1016/j.annder.2019.01.018] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2018] [Revised: 11/24/2018] [Accepted: 01/23/2019] [Indexed: 01/29/2023]
Affiliation(s)
- L Jelti
- Service de dermatologie, Inserm U1234, université de Normandie, CHU de Rouen, 1 rue de Germont, 76000 Rouen, France.
| | - C Prost-Squarcioni
- Service de dermatologie, université Paris 13, hôpital Avicenne, AP-HP, 93000 Bobigny, France
| | - S Ingen-Housz-Oro
- Service de dermatologie, hôpital Henri-Mondor, AP-HP, 94000 Créteil, France
| | - F Caux
- Service de dermatologie, université Paris 13, hôpital Avicenne, AP-HP, 93000 Bobigny, France
| | - P Bernard
- Service de dermatologie, hôpital Robert-Debré, CHU de Reims, 51092 Reims, France
| | - C Bedane
- Service de dermatologie, hôpital Dupuytren, 87042 Limoges, France
| | - M Alexandre
- Service de dermatologie, université Paris 13, hôpital Avicenne, AP-HP, 93000 Bobigny, France
| | - O Dereure
- Service de dermatologie, Inserm U1058, université de Montpellier, hôpital St-Eloi, 34295 Montpellier, France
| | - G Quereux
- Service de dermatologie, CHU Hôtel-Dieu, 44093 Nantes, France
| | - E Le Bidre
- Service de dermatologie, hôpital Trousseau, CHRU de Tours, 37044 Tours, France
| | - J Plée
- Service de dermatologie, hôpital Robert-Debré, CHU de Reims, 51092 Reims, France
| | - C Picard-Dahan
- Service de dermatologie, hôpital Bichat-Claude-Bernard, AP-HP, 75018 Paris, France
| | - C Le Roux-Villet
- Service de dermatologie, université Paris 13, hôpital Avicenne, AP-HP, 93000 Bobigny, France
| | - S Duvert-Lehembre
- Service de dermatologie, hôpital Claude-Huriez, CHRU de Lille, 59037 Lille, France
| | - M-A Richard
- EA3279 : CEReSS-centre d'étude et de recherche sur les services de santé et la qualité de vie, service de dermatologie, université Aix-Marseille, hôpital de La Timone, Assistance publique-Hôpitaux de Marseille, 13385 Marseille, France
| | - E Delaporte
- Service de dermatologie, université Aix-Marseille, hôpital Nord, Assistance publique-Hôpitaux de Marseille, 13385 Marseille, France
| | - S Debarbieux
- Service de dermatologie, hôpital Edouard-Herriot, hospices civils de Lyon, 69437 Lyon, France
| | - D Jullien
- Service de dermatologie, hôpital Edouard-Herriot, hospices civils de Lyon, 69437 Lyon, France
| | - M D'Incan
- Service de dermatologie, CHU Estaing, 63000 Clermont-Ferrand, France
| | - M-P Konstantinou
- Service de dermatologie, hôpital Larrey, CHU de Toulouse, 31059 Toulouse, France
| | - J-D Bouaziz
- Service de dermatologie, hôpital Saint-Louis, AP-HP, 75010 Paris, France
| | - E Tancrède-Bohin
- Service de dermatologie, hôpital Saint-Louis, AP-HP, 75010 Paris, France
| | - M-S Doutre
- Service de dermatologie, hôpital Saint-André, CHU de Bordeaux, 33000 Bordeaux, France
| | - I Bourgault Villada
- Service de dermatologie, hôpital Ambroise-Paré, AP-HP, 92100 Boulogne-Billancourt, France
| | - N Cordel
- Service de dermatologie, Inserm U1234, université de Normandie, CHU de Rouen, 1 rue de Germont, 76000 Rouen, France; Unité de dermatologie-immunologie clinique, CHU de Guadeloupe, 97159 Pointe-à-Pitre cedex, Guadeloupe
| | - B Sassolas
- Service de médecine interne et pneumologie, hôpital de la Cavale-Blanche, CHRU de Brest, 29609 Brest, France
| | - M-A Viguier
- Service de dermatologie, hôpital Robert-Debré, CHU de Reims, 51092 Reims, France
| | - B Mellottée
- Service de dermatologie, université Paris 13, hôpital Avicenne, AP-HP, 93000 Bobigny, France
| | - F Jouen
- Inserm U1234, laboratoire d'immunologie, université de Normandie, CHU de Rouen, 76000 Rouen, France
| | - V Hebert
- Service de dermatologie, Inserm U1234, université de Normandie, CHU de Rouen, 1 rue de Germont, 76000 Rouen, France
| | - P Joly
- Service de dermatologie, Inserm U1234, université de Normandie, CHU de Rouen, 1 rue de Germont, 76000 Rouen, France
| | -
- Service de dermatologie, Inserm U1234, université de Normandie, CHU de Rouen, 1 rue de Germont, 76000 Rouen, France; Service de dermatologie, université Paris 13, hôpital Avicenne, AP-HP, 93000 Bobigny, France; Service de dermatologie, hôpital Henri-Mondor, AP-HP, 94000 Créteil, France; Service de dermatologie, hôpital Robert-Debré, CHU de Reims, 51092 Reims, France; Service de dermatologie, hôpital Dupuytren, 87042 Limoges, France; Service de dermatologie, Inserm U1058, université de Montpellier, hôpital St-Eloi, 34295 Montpellier, France; Service de dermatologie, CHU Hôtel-Dieu, 44093 Nantes, France; Service de dermatologie, hôpital Trousseau, CHRU de Tours, 37044 Tours, France; Service de dermatologie, hôpital Bichat-Claude-Bernard, AP-HP, 75018 Paris, France; Service de dermatologie, hôpital Claude-Huriez, CHRU de Lille, 59037 Lille, France; EA3279 : CEReSS-centre d'étude et de recherche sur les services de santé et la qualité de vie, service de dermatologie, université Aix-Marseille, hôpital de La Timone, Assistance publique-Hôpitaux de Marseille, 13385 Marseille, France; Service de dermatologie, université Aix-Marseille, hôpital Nord, Assistance publique-Hôpitaux de Marseille, 13385 Marseille, France; Service de dermatologie, hôpital Edouard-Herriot, hospices civils de Lyon, 69437 Lyon, France; Service de dermatologie, CHU Estaing, 63000 Clermont-Ferrand, France; Service de dermatologie, hôpital Larrey, CHU de Toulouse, 31059 Toulouse, France; Service de dermatologie, hôpital Saint-Louis, AP-HP, 75010 Paris, France; Service de dermatologie, hôpital Saint-André, CHU de Bordeaux, 33000 Bordeaux, France; Service de dermatologie, hôpital Ambroise-Paré, AP-HP, 92100 Boulogne-Billancourt, France; Unité de dermatologie-immunologie clinique, CHU de Guadeloupe, 97159 Pointe-à-Pitre cedex, Guadeloupe; Service de médecine interne et pneumologie, hôpital de la Cavale-Blanche, CHRU de Brest, 29609 Brest, France; Inserm U1234, laboratoire d'immunologie, université de Normandie, CHU de Rouen, 76000 Rouen, France
| | -
- Service de dermatologie, Inserm U1234, université de Normandie, CHU de Rouen, 1 rue de Germont, 76000 Rouen, France; Service de dermatologie, université Paris 13, hôpital Avicenne, AP-HP, 93000 Bobigny, France; Service de dermatologie, hôpital Henri-Mondor, AP-HP, 94000 Créteil, France; Service de dermatologie, hôpital Robert-Debré, CHU de Reims, 51092 Reims, France; Service de dermatologie, hôpital Dupuytren, 87042 Limoges, France; Service de dermatologie, Inserm U1058, université de Montpellier, hôpital St-Eloi, 34295 Montpellier, France; Service de dermatologie, CHU Hôtel-Dieu, 44093 Nantes, France; Service de dermatologie, hôpital Trousseau, CHRU de Tours, 37044 Tours, France; Service de dermatologie, hôpital Bichat-Claude-Bernard, AP-HP, 75018 Paris, France; Service de dermatologie, hôpital Claude-Huriez, CHRU de Lille, 59037 Lille, France; EA3279 : CEReSS-centre d'étude et de recherche sur les services de santé et la qualité de vie, service de dermatologie, université Aix-Marseille, hôpital de La Timone, Assistance publique-Hôpitaux de Marseille, 13385 Marseille, France; Service de dermatologie, université Aix-Marseille, hôpital Nord, Assistance publique-Hôpitaux de Marseille, 13385 Marseille, France; Service de dermatologie, hôpital Edouard-Herriot, hospices civils de Lyon, 69437 Lyon, France; Service de dermatologie, CHU Estaing, 63000 Clermont-Ferrand, France; Service de dermatologie, hôpital Larrey, CHU de Toulouse, 31059 Toulouse, France; Service de dermatologie, hôpital Saint-Louis, AP-HP, 75010 Paris, France; Service de dermatologie, hôpital Saint-André, CHU de Bordeaux, 33000 Bordeaux, France; Service de dermatologie, hôpital Ambroise-Paré, AP-HP, 92100 Boulogne-Billancourt, France; Unité de dermatologie-immunologie clinique, CHU de Guadeloupe, 97159 Pointe-à-Pitre cedex, Guadeloupe; Service de médecine interne et pneumologie, hôpital de la Cavale-Blanche, CHRU de Brest, 29609 Brest, France; Inserm U1234, laboratoire d'immunologie, université de Normandie, CHU de Rouen, 76000 Rouen, France
| |
Collapse
|
26
|
Berkani N, Joly P, Golinski ML, Colliou N, Lim A, Larbi A, Riou G, Caillot F, Bernard P, Bedane C, Delaporte E, Chaby G, Dompmartin A, Hertl M, Calbo S, Musette P. B-cell depletion induces a shift in self antigen specific B-cell repertoire and cytokine pattern in patients with bullous pemphigoid. Sci Rep 2019; 9:3525. [PMID: 30837635 PMCID: PMC6401188 DOI: 10.1038/s41598-019-40203-7] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2018] [Accepted: 02/04/2019] [Indexed: 11/08/2022] Open
Abstract
Bullous Pemphigoid is the most common auto-immune bullous skin disease. It is characterized by the production of auto-antibodies directed against 2 proteins of the hemi-desmosome (BP180 and BP230). We assessed the efficacy and mechanisms of action of rituximab, an anti-CD20 monoclonal antibody, in 17 patients with severe and relapsing type of bullous pemphigoid. The phenotype, cytokine gene expression, and rearrangement of BP180-specific B-cell receptor genes were performed over 2 years following treatment. At the end of the study, 5 patients had died, 3 had withdrawn from the study, and 9 patients were in complete remission. The one- and two-year relapse rates were 44.1% (95% Confidence Interval (CI): 21.0-76.0%) and 66.5%, (95% CI: 38.4-91.4%), respectively. Phenotypic analyses confirmed dramatic B-cell depletion, which lasted for 9 to 12 months. The ELISA values of serum anti-BP180 antibodies and the frequency of BP180-specific circulating B cells decreased dramatically following treatment, which paralleled the improvement of skin lesions. During B-cell reconstitution, a polyclonal IgM repertoire appeared and a shift in the rearrangement of the B-cell receptor genes of BP180-specific circulating B cells was observed. Concurrently, we observed a decrease of IL-15, IL-6 and TNFα expressing BP180-specific B cells, and the emergence of IL-10 and IL-1RA-expressing BP180-specific IgM+ B cells in patients in complete remission off therapy, suggesting the functional plasticity of BP180-specific auto-immune B cells after rituximab treatment.
Collapse
Affiliation(s)
| | - Pascal Joly
- Normandie University, UNIROUEN, INSERM U1234, Rouen, France
- Normandie University, UNIROUEN, Rouen University Hospital, Department of Dermatology, French reference center for autoimmune bullous diseases, F76000, Rouen, France
| | - Marie-Laure Golinski
- Normandie University, UNIROUEN, INSERM U1234, Rouen, France
- Normandie University, UNIROUEN, Rouen University Hospital, Department of Dermatology, French reference center for autoimmune bullous diseases, F76000, Rouen, France
| | | | - Annick Lim
- Immunoscope plateform, Pasteur Institute, Paris, France
| | - Anis Larbi
- Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore
| | - Gaetan Riou
- Normandie University, UNIROUEN, INSERM U1234, Rouen, France
| | | | - Philippe Bernard
- Department of Dermatology, Reims University Hospital, Reims, France
| | - Christophe Bedane
- Department of Dermatology, Limoges University Hospital, Limoges, France
| | | | - Guillaume Chaby
- Department of Dermatology, Amiens University Hospital, Amiens, France
| | - Anne Dompmartin
- Department of Dermatology, Caen University Hospital, Caen, France
| | - Michael Hertl
- Department of Dermatology and Allergology, Philipps University, Marburg, Germany
| | | | - Philippe Musette
- Normandie University, UNIROUEN, Rouen University Hospital, Department of Dermatology, French reference center for autoimmune bullous diseases, F76000, Rouen, France.
- INSERM U976, Saint Louis Hospital, Paris, France.
| |
Collapse
|
27
|
Jelti L, Cordel N, Gillibert A, Lacour JP, Uthurriague C, Doutre MS, Delaporte E, Duvert-Lehembre S, Quereux G, Dupuy A, Adamski H, Bedane C, Misery L, Abasq Thomas C, Fleuret C, Bernard P, Chaby G, D'incan M, Verneuil L, Litrowski N, Joly P. Incidence and Mortality of Pemphigus in France. J Invest Dermatol 2019; 139:469-473. [DOI: 10.1016/j.jid.2018.07.042] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2018] [Revised: 07/13/2018] [Accepted: 07/27/2018] [Indexed: 10/28/2022]
|
28
|
Hébert V, Boulard C, Houivet E, Duvert Lehembre S, Borradori L, Della Torre R, Feliciani C, Fania L, Zambruno G, Camaioni DB, Didona B, Marinovic B, Schmidt E, Schumacher N, Hünefeld C, Schanz S, Kern JS, Hofmann S, Bouyeure AC, Picard-Dahan C, Prost-Squarcioni C, Caux F, Alexandre M, Ingen-Housz-Oro S, Bagot M, Tancrede-Bohin E, Bouaziz JD, Franck N, Vabres P, Labeille B, Richard MA, Delaporte E, Dupuy A, D’Incan M, Quereux G, Skowro F, Paul C, Livideanu CB, Beylot-Barry M, Doutre MS, Avenel-Audran M, Bedane C, Bernard P, Machet L, Maillard H, Jullien D, Debarbieux S, Sassolas B, Misery L, Abasq C, Dereure O, Lagoutte P, Ferranti V, Werth VP, Murrell DF, Hertl M, Benichou J, Joly P. Large International Validation of ABSIS and PDAI Pemphigus Severity Scores. J Invest Dermatol 2019; 139:31-37. [DOI: 10.1016/j.jid.2018.04.042] [Citation(s) in RCA: 44] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2017] [Revised: 04/20/2018] [Accepted: 04/25/2018] [Indexed: 11/29/2022]
|
29
|
Hebert V, Vermeulin T, Prost-Squarcioni C, Picard-Dahan C, Duvert-Lehembre S, Bruno L, Marie-Aleth R, Bernard P, Dupuy A, Bouaziz JD, Oro S, Dalac-Rat S, Delaporte E, Avenel-Audran M, Sassolas B, Alexandre M, Caux F, D’Incan M, Bedane C, Quereux G, Machet L, Dereure O, Skowron F, Franck N, Beylot-Barry M, Doutre MS, Debarbieux S, Jullien D, Misery L, Musette P, Paul C, Vabres P, Bénéton N, Dupin N, Houivet E, Joly P. Comparaison des coûts de santé du traitement de première ligne par rituximab par rapport à la corticothérapie standard chez les patients pemphigus nouvellement diagnostiqués. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
30
|
Delaumenie S, Assikar S, Prud’homme R, Matei I, Couture M, Souyri N, Couraud A, Bedane C. Efficacité et tolérance du méthotrexate dans la pemphigoïde bulleuse en Limousin. Étude rétrospective de 52 patients. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
31
|
Pittoni J, Bedane C, Diabate A, Couture M, Prud’homme R, Matei I, Assikar S, Audevard D. Efficacité d’un anti-IL6 dans deux cas de pemphigoïde bulleuse sévère. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
32
|
Douard P, Prud’Homme R, Assikar S, Matei I, Bourgaux M, Jaccard A, Bedane C. Association myélome et dermatose à IgA intra-épidermique. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
33
|
Marcaillou M, Bourgaux M, Prud’homme R, Matei I, Assikar S, Bedane C. Efficacité de l’imatinib (Glivec®) sur deux mélanomes muqueux métastatiques mutés KIT. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.517] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
34
|
|
35
|
Masmoudi W, Hebert V, Quéreux G, Bedane C, Prost-Squarcioni C, Debarbieux S, Oro S, Chaby G, D’incan M, Litrowski N, Boulard C, Roussel A, Kottler D, Abasq C, Richard MA, Duvert-Lehembre S, Gottlieb J, Plantin P, Joly P. Calcul des valeurs seuils du score BPDAI (Bullous Pemphigoid Disease Area Index) définissant les formes légères, modérées et sévères de la pemphigoïde bulleuse. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
36
|
Jelti L, Cordel N, Gillibert A, Lacour JP, Uthurriague C, Doutre MS, Delaporte E, Duvert-Lehembre S, Quereux G, Dupuy A, Adamski H, Bedane C, Misery L, Abasq Thomas C, Fleuret C, Bernard P, Chaby G, D’incan M, Verneuil L, Litrowski N, Joly P. Mortalité du pemphigus et facteurs pronostiques, incluant les traitements initialement proposés. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
37
|
Naqi A, Bedane C, Souyri N, Diabaté A. Photosensibilité persistante au verteporfin. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
38
|
Richard MA, Lacour JP, Konstantinou MP, Ruer-Mulard M, Bedane C, Misery L, Martin L, Aubron-Olivier C, Chalmers R. Évaluation de l’efficacité du secukinumab à l’aide de l’indice simplifié du Psoriasis : résultat d’une étude clinique prospective. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.427] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
39
|
Douard P, Assikar S, Matei I, Prud’homme R, Audevar D, Bedane C. Pemphigus vulgaire et réactivation virale. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
40
|
Delyon J, Chevret S, Jouary T, Dalac S, Dalle S, Guillot B, Arnault JP, Avril MF, Bedane C, Bens G, Pham-Ledard A, Mansard S, Grange F, Machet L, Meyer N, Legoupil D, Saiag P, Idir Z, Renault V, Deleuze JF, Hindie E, Battistella M, Dumaz N, Mourah S, Lebbe C. STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network. J Invest Dermatol 2017; 138:58-67. [PMID: 28843487 DOI: 10.1016/j.jid.2017.07.839] [Citation(s) in RCA: 44] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2017] [Revised: 06/18/2017] [Accepted: 07/14/2017] [Indexed: 01/30/2023]
Abstract
Mutated oncogenic KIT is a therapeutic target in melanoma. We conducted a multicenter phase II trial on the KIT inhibitor nilotinib in patients with unresectable melanoma harboring KIT alteration. The primary endpoint was the response rate (complete response or partial response following Response Evaluation Criteria in Solid Tumors criteria) at 6 months. Pharmacodynamic studies using KIT sequencing, qPCR array, and immunostaining of downstream KIT effectors were performed during treatment. Twenty-five patients were included and received 400 mg oral nilotinib twice daily. At 6 months, nilotinib induced tumor response in four patients. The best overall response rate was 20% and the disease control rate was 56%, limited to patients harboring exon 11 or 13 mutations. Four patients exhibited durable response, including three persisting (3.6 and 2.8 years for two patients with stage IIIC and 2.5 years for one with IVM1b melanoma). A reduction in signal transducer and activator of transcription (STAT) 3 phosphorylation and its effectors (BCL-2, MCL-1) in tumors during follow-up was significantly associated with clinical response. In the KIT-mutated melanoma cell line M230, nilotinib reduced STAT3 signaling and STAT inhibitors were as efficient as KIT inhibitors in reducing cell proliferation. Our study evidences a significant association between STAT3 inhibition and response to nilotinib, and provides a rationale for future research assessing STAT inhibitors in KIT-mutated melanoma.
Collapse
Affiliation(s)
- Julie Delyon
- Service de Dermatologie, and CIC (Centre d'Investigations Cliniques), AP-HP, Hôpital Saint-Louis, Paris, France; INSERM, UMR-976, AP-HP, Hôpital Saint-Louis, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris, France.
| | - Sylvie Chevret
- Université Paris Diderot, Sorbonne Paris Cité, Paris, France; Service de Biostatistique et Information Médicale, AP-HP, Hôpital Saint-Louis, Paris, France
| | - Thomas Jouary
- Unité Onco-dermatologie, Hôpital François Mitterrand, Pau, France
| | - Sophie Dalac
- Service de Dermatologie, CHU Dijon Bourgogne, Dijon, France
| | - Stephane Dalle
- Cancer Research Center of Lyon, INSERM U1052, CNRS UMR5286, Claude Bernard Lyon 1 University, Institut de Cancérologie des Hospices Civils de Lyon, Lyon, France
| | | | | | - Marie-Françoise Avril
- Service de Dermatologie, AP-HP, Hôpital Cochin, Paris, France; Université Paris Descartes, Paris, France
| | - Christophe Bedane
- Unité d'oncologie thoracique et cutanée, Hopital Dupuytren, Limoges, France
| | - Guido Bens
- Service de Dermatologie, Centre hospitalier régional d'Orléans, Orléans, France
| | | | - Sandrine Mansard
- Dermatology Department, CHU de Clermont Ferrand, Clermont Ferrand, France
| | - Florent Grange
- Dermatology Department, Reims University Hospital, Reims, France
| | - Laurent Machet
- Department of Dermatology, Centre Hospitalier Regional et Universitaire (CHRU) de Tours, Tours, France; Inserm U930, University Francois Rabelais de Tours, Tours, France
| | - Nicolas Meyer
- Dermatologie, Institut Universitaire du Cancer et CHU de Toulouse, Toulouse, France; Inserm UMR 1037, CRCT, Toulouse, France
| | | | - Philippe Saiag
- Université de Versailles St-Quentin, EA 4340, Boulogne-Billancourt, France; Service de Dermatologie Générale et Oncologique, AP-HP, Hôpital Ambroise Paré, Boulogne-Billancourt, France
| | - Zakia Idir
- AP-HP, Département de la Recherche Clinique et du Développement, AP-HP, Hôpital Saint-Louis, Paris, France
| | - Victor Renault
- Laboratory for Bioinformatics, CEPH-Fondation Jean Dausset, Paris, France
| | - Jean-François Deleuze
- Centre National de Génotypage, CEA, Evry, France; CEPH-Fondation Jean Dausset, Paris, France
| | - Elif Hindie
- Service de Médecine Nucléaire, CHU de Bordeaux, LabEx TRAIL, Université de Bordeaux, Bordeaux, France
| | - Maxime Battistella
- Université Paris Diderot, Sorbonne Paris Cité, Paris, France; INSERM, UMR_S1165, Paris, France; Pathology department, Hopital Saint-Louis, AP-HP, Paris, France
| | - Nicolas Dumaz
- INSERM, UMR-976, AP-HP, Hôpital Saint-Louis, Paris, France
| | - Samia Mourah
- INSERM, UMR-976, AP-HP, Hôpital Saint-Louis, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris, France; Laboratoire de Pharmacologie Biologique, AP-HP, Hôpital Saint-Louis, Paris, France
| | - Celeste Lebbe
- Service de Dermatologie, and CIC (Centre d'Investigations Cliniques), AP-HP, Hôpital Saint-Louis, Paris, France; INSERM, UMR-976, AP-HP, Hôpital Saint-Louis, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | | |
Collapse
|
41
|
Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, Caillot F, Golinski ML, Labeille B, Picard-Dahan C, Paul C, Richard MA, Bouaziz JD, Duvert-Lehembre S, Bernard P, Caux F, Alexandre M, Ingen-Housz-Oro S, Vabres P, Delaporte E, Quereux G, Dupuy A, Debarbieux S, Avenel-Audran M, D'Incan M, Bedane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Vermeulin T, Benichou J, Musette P. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet 2017; 389:2031-2040. [PMID: 28342637 DOI: 10.1016/s0140-6736(17)30070-3] [Citation(s) in RCA: 347] [Impact Index Per Article: 49.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/14/2016] [Revised: 11/07/2016] [Accepted: 11/16/2016] [Indexed: 02/07/2023]
Abstract
BACKGROUND High doses of corticosteroids are considered the standard treatment for pemphigus. Because long-term corticosteroid treatment can cause severe and even life-threatening side-effects in patients with this disease, we assessed whether first-line use of rituximab as adjuvant therapy could improve the proportion of patients achieving complete remission off-therapy, compared with corticosteroid treatment alone, while decreasing treatment side-effects of corticosteroids. METHODS We did a prospective, multicentre, parallel-group, open-label, randomised trial in 25 dermatology hospital departments in France (Ritux 3). Eligible participants were patients with newly diagnosed pemphigus aged 18-80 years being treated for the first time (not at the time of a relapse). We randomly assigned participants (1:1) to receive either oral prednisone alone, 1·0 or 1·5 mg/kg per day tapered over 12 or 18 months (prednisone alone group), or 1000 mg of intravenous rituximab on days 0 and 14, and 500 mg at months 12 and 18, combined with a short-term prednisone regimen, 0·5 or 1·0 mg/kg per day tapered over 3 or 6 months (rituximab plus short-term prednisone group). Follow-up was for 3 years (study visits were scheduled weekly during the first month of the study, then monthly until month 24, then an additional visit at month 36). Treatment was assigned through central computer-generated randomisation, with stratification according to disease-severity (severe or moderate, based on Harman's criteria). The primary endpoint was the proportion of patients who achieved complete remission off-therapy at month 24 (intention-to-treat analysis). This study is registered with ClinicalTrials.gov, number NCT00784589. FINDINGS Between May 10, 2010, and Dec 7, 2012, we enrolled 91 patients and randomly assigned 90 to treatment (90 were analysed; 1 patient withdrew consent before the random assignment). At month 24, 41 (89%) of 46 patients assigned to rituximab plus short-term prednisone were in complete remission off-therapy versus 15 (34%) of 44 assigned to prednisone alone (absolute difference 55 percentage points, 95% CI 38·4-71·7; p<0·0001. This difference corresponded to a relative risk of success of 2·61 (95% CI 1·71-3·99, p<0·0001), corresponding to 1·82 patients (95% CI 1·39-2·60) who would need to be treated with rituximab plus prednisone (rather than prednisone alone) for one additional success. No patient died during the study. More severe adverse events of grade 3-4 were reported in the prednisone-alone group (53 events in 29 patients; mean 1·20 [SD 1·25]) than in the rituximab plus prednisone group (27 events in 16 patients; mean 0·59 [1·15]; p=0·0021). The most common of these events in both groups were diabetes and endocrine disorder (11 [21%] with prednisone alone vs six [22%] with rituximab plus prednisone), myopathy (ten [19%] vs three [11%]), and bone disorders (five [9%] vs five [19%]). INTERPRETATION Data from our trial suggest that first-line use of rituximab plus short-term prednisone for patients with pemphigus is more effective than using prednisone alone, with fewer adverse events. FUNDING French Ministry of Health, French Society of Dermatology, Roche.
Collapse
Affiliation(s)
- Pascal Joly
- Department of Dermatology, Rouen University Hospital and INSERM U1234, Centre de référence des maladies bulleuses autoimmunes, Normandie University, Rouen, France.
| | - Maud Maho-Vaillant
- Department of Dermatology, Rouen University Hospital and INSERM U1234, Centre de référence des maladies bulleuses autoimmunes, Normandie University, Rouen, France
| | | | - Vivien Hebert
- Department of Dermatology, Rouen University Hospital and INSERM U1234, Centre de référence des maladies bulleuses autoimmunes, Normandie University, Rouen, France
| | - Estelle Houivet
- Department of Biostatistics, Rouen University Hospital and INSERM U1219, Normandie University, Rouen, France
| | - Sébastien Calbo
- Department of Dermatology, Rouen University Hospital and INSERM U1234, Centre de référence des maladies bulleuses autoimmunes, Normandie University, Rouen, France
| | - Frédérique Caillot
- Department of Dermatology, Rouen University Hospital and INSERM U1234, Centre de référence des maladies bulleuses autoimmunes, Normandie University, Rouen, France
| | - Marie Laure Golinski
- Department of Dermatology, Rouen University Hospital and INSERM U1234, Centre de référence des maladies bulleuses autoimmunes, Normandie University, Rouen, France
| | - Bruno Labeille
- Department of Dermatology, University of Saint Etienne, Saint Etienne, France
| | | | - Carle Paul
- Department of Dermatology, University of Toulouse, Toulouse, France
| | - Marie-Aleth Richard
- Department of Dermatology, Assistance Publique des Hopitaux de Marseille, Aix Marseille University, UMR 911, INSERM CRO2, Marseille, France
| | - Jean David Bouaziz
- Department of Dermatology of St Louis Hospital, Paris 7 Sorbonne Paris Cité University, Paris, France
| | - Sophie Duvert-Lehembre
- Department of Dermatology, Rouen University Hospital and INSERM U1234, Centre de référence des maladies bulleuses autoimmunes, Normandie University, Rouen, France
| | | | - Frederic Caux
- Department of Dermatology, University of Paris XIII, Bobigny, France
| | - Marina Alexandre
- Department of Dermatology, University of Paris XIII, Bobigny, France
| | | | - Pierre Vabres
- Department of Dermatology Dijon University Hospital, Dijon, France
| | | | - Gaelle Quereux
- Department of Dermatology, University of Nantes, Nantes, France
| | - Alain Dupuy
- Department of Dermatology, University of Rennes, Rennes, France
| | - Sebastien Debarbieux
- Department of Dermatology, Centre Hospitalier Lyon Sud; Pierre Bénite, Lyon, France
| | | | - Michel D'Incan
- Department of Dermatology, University of Clermont-Ferrand, Clermont-Ferrand, France
| | | | - Nathalie Bénéton
- Department of Dermatology, Le Mans General Hospital, Le Mans, France
| | - Denis Jullien
- Department of Dermatology, Edouard Herriot Hospital, Lyon Claude Bernard University, Lyon, France
| | - Nicolas Dupin
- Department of Dermatology, University of Paris V, Paris, France
| | - Laurent Misery
- Department of Dermatology, Brest University Hospital, Brest, France
| | - Laurent Machet
- Department of Dermatology, Tours University Hospital, Tours, France
| | | | - Olivier Dereure
- Department of Dermatology, University of Montpellier, Montpellier, France
| | - Bruno Sassolas
- Department of Internal Medicine, Brest University Hospital, Brest, France
| | - Thomas Vermeulin
- Department of Medical Information and Informatics, Rouen University Hospital, Rouen, France
| | - Jacques Benichou
- Department of Biostatistics, Rouen University Hospital and INSERM U1219, Normandie University, Rouen, France
| | - Philippe Musette
- Department of Dermatology, Rouen University Hospital and INSERM U1234, Centre de référence des maladies bulleuses autoimmunes, Normandie University, Rouen, France
| |
Collapse
|
42
|
Delaumenie S, Assikar S, Matei I, Souyri N, Audevard D, Bedane C. Psoriasis et pemphigoïde bulleuse. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.292] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
43
|
Jelti L, Le Bourhis-Zaimi M, Lacour JP, Uthurriague C, Doutre MS, Delaporte E, Duvert-Lehembre S, Quereux G, Dupuy A, Adamski H, Bedane C, Misery L, Abasq Thomas C, Fleuret C, Bernard P, Chaby G, D’incan M, Verneuil L, Litrowski N, Joly P. Incidence et mortalité du pemphigus en France. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.147] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
44
|
Woillard JB, Maffioletti PF, Assikar S, Monchaud C, Marquet P, Couraud A, Matei I, Bedane C. Intérêt du suivi thérapeutique pharmacologique de l’acide mycophénolique chez des patients traités pour pemphigoïde cicatricielle. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
45
|
Couture M, Laumonier J, Audevard D, Assikar S, Bordes S, Closs B, Bedane C. L’IL6 est significativement augmentée dans les formes sévères de pemphigoïde bulleuse. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.294] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
46
|
Bonigen J, Raynaud-Donzel C, Hureaux J, Kramkimel N, Blom A, Jeudy G, Breton AL, Hubiche T, Bedane C, Legoupil D, Pham-Ledard A, Charles J, Pérol M, Gérard E, Combemale P, Bonnet D, Sigal ML, Mahé E. Anti-PD1-induced psoriasis: a study of 21 patients. J Eur Acad Dermatol Venereol 2016; 31:e254-e257. [PMID: 27739129 DOI: 10.1111/jdv.14011] [Citation(s) in RCA: 126] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- J Bonigen
- Service de Dermatologie, Hôpital Victor Dupouy, Argenteuil, France
| | - C Raynaud-Donzel
- Service de Pneumologie, Hôpital Victor Dupouy, Argenteuil, France
| | - J Hureaux
- Service de Pneumologie, Centre Hospitalier Universitaire, Angers, France
| | - N Kramkimel
- Service de Dermatologie, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - A Blom
- Service de Dermatologie Générale et Oncologique, Centre Hospitalier Universitaire Ambroise Paré, Assistance Publique-Hôpitaux de Paris, Boulogne-Billancourt, France
| | - G Jeudy
- Service de Dermatologie, Centre Hospitalier Universitaire François Mitterrand, Dijon, France
| | - A-L Breton
- Service de Dermatologie, Centre Hospitalier Universitaire de Lyon Sud, Lyon, France
| | - T Hubiche
- Unité de Dermatologie Infectiologie, Centre Hospitalier Intercommunal de Fréjus/Saint-Raphaël, Fréjus, France
| | - C Bedane
- Service de Dermatologie, Centre Hospitalier Universitaire de Limoges, Limoges, France
| | - D Legoupil
- Service de Dermatologie, Centre Hospitalier Régional et Universitaire de Brest, Brest, France
| | - A Pham-Ledard
- Service de Dermatologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
| | - J Charles
- Service de Dermatologie, CHU Grenoble, Grenoble, France
| | - M Pérol
- Département de Cancérologie Médicale, Centre Léon Bérard, Lyon, France
| | - E Gérard
- Service de Dermatologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
| | - P Combemale
- Unité d'Onco-Dermatolgie, Centre Léon Bérard, Lyon, France
| | - D Bonnet
- Service de Dermatologie Générale et Oncologique, Centre Hospitalier Universitaire Ambroise Paré, Assistance Publique-Hôpitaux de Paris, Boulogne-Billancourt, France
| | - M-L Sigal
- Service de Dermatologie, Hôpital Victor Dupouy, Argenteuil, France
| | - E Mahé
- Service de Dermatologie, Hôpital Victor Dupouy, Argenteuil, France
| | | |
Collapse
|
47
|
Rigot E, Cypierre A, Liozon E, Bézananary H, Gondran G, Ly K, Fauchais A, Bedane C, Palat S. Prise en charge de la douleur engendrée par les ulcérations digitales dans la sclérodermie : résultats d’une enquête de pratique. Rev Med Interne 2016. [DOI: 10.1016/j.revmed.2016.04.233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
48
|
Boulard C, Duvert Lehembre S, Picard‐Dahan C, Kern J, Zambruno G, Feliciani C, Marinovic B, Vabres P, Borradori L, Prost‐Squarcioni C, Labeille B, Richard M, Ingen‐Housz‐Oro S, Houivet E, Werth V, Murrell D, Hertl M, Benichou J, Joly P, Hofmann S, Camaioni B, Didona B, Fania L, Della Torre R, Caux F, Alexandre M, Paul C, Bulai Livideanu C, Delaporte E, Dupuy A, Avenel‐Audran M, Schmidt E, Schumacher N, Bagot M, Tancrede‐Bohin E, Bouaziz J, D'Incan M, Quereux G, Skowron F, Beylot‐Barry M, Doutre M, Bedane C, Bernard P, Machet L, Jullien ., Debarbieux S, Dereure O, Hünefeld C, Schanz S, Franck N, Maillard H, Misery L, Sassolas B, Abasq C, Bouyeure A, Lagoutte P, Ferranti V. Calculation of cut‐off values based on the Autoimmune Bullous Skin Disorder Intensity Score (
ABSIS
) and Pemphigus Disease Area Index (
PDAI
) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus. Br J Dermatol 2016; 175:142-9. [DOI: 10.1111/bjd.14405] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/14/2016] [Indexed: 11/27/2022]
Affiliation(s)
- C. Boulard
- Department of Dermatology Rouen University Hospital, and INSERM U905 Institute for Research and Innovation in Biomedicine University of Rouen Rouen France
| | - S. Duvert Lehembre
- Department of Dermatology Rouen University Hospital, and INSERM U905 Institute for Research and Innovation in Biomedicine University of Rouen Rouen France
| | - C. Picard‐Dahan
- Department of Dermatology Bichat University Hospital AP‐HP Paris France
| | - J.S. Kern
- Department of Dermatology Medical Center University of Freiburg Freiburg Germany
| | - G. Zambruno
- Laboratory of Molecular and Cell Biology Istituto Dermopatico dell'Immacolata IRCCS Via Monti di Creta 104 00167 Roma Italy
| | - C. Feliciani
- Policlinico Gemelli – Università Cattolica del ‘Sacro Cuore’ Largo Gemelli 8 00168 Roma Italy
| | - B. Marinovic
- University Hospital Center Zagreb Department of Dermatology and Venereology Salata 4 10000 Zagreb Croatia
| | - P. Vabres
- Department of Dermatology Dijon University Hospital Dijon France
| | - L. Borradori
- Department of Dermatology Universitätsklinik für Dermatologie Inselspital CH‐3010 Bern Switzerland
| | - C. Prost‐Squarcioni
- Department of Dermatology Avicenne Hospital University Paris 13 Bobigny France
| | - B. Labeille
- Department of Dermatology Saint Etienne University Hospital Saint Etienne France
| | - M.A. Richard
- Aix‐Marseille University UMR 911 INSERM CRO2 ‘Centre de Recherche en Oncologie Biologique et Oncophamacologie’ Department of Dermatology Hôpital Timone Assistance Publique des Hôpitaux de Marseille 264 Rue Saint Pierre 13385 Marseille France
| | - S. Ingen‐Housz‐Oro
- Department of Dermatology Henri Mondor University Hospital AP‐HP Créteil France
| | - E. Houivet
- Department of Biostatistics INSERM U657 Rouen University Hospital University of Rouen Rouen France
| | - V.P. Werth
- Department of Dermatology University of Pennsylvania, and Philadelphia VAMC Philadelphia PA U.S.A
| | - D.F. Murrell
- Department of Dermatology St George Hospital University of NSW Sydney Australia
| | - M. Hertl
- Department of Dermatology Philipps University Marburg Marburg Germany
| | - J. Benichou
- Department of Biostatistics INSERM U657 Rouen University Hospital University of Rouen Rouen France
| | - P. Joly
- Department of Dermatology Rouen University Hospital, and INSERM U905 Institute for Research and Innovation in Biomedicine University of Rouen Rouen France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Houx L, Hachulla E, Kone-Paut I, Quartier P, Touitou I, Guennoc X, Grateau G, Hamidou M, Neven B, Berthelot JM, Lequerré T, Pillet P, Lemelle I, Fischbach M, Duquesne A, Le Blay P, Le Jeunne C, Stirnemann J, Bonnet C, Gaillard D, Alix L, Touraine R, Garcier F, Bedane C, Jurquet AL, Duffau P, Smail A, Frances C, Grall-Lerosey M, Cathebras P, Tran TA, Morell-Dubois S, Pagnier A, Richez C, Cuisset L, Devauchelle-Pensec V. Musculoskeletal symptoms in patients with cryopyrin-associated periodic syndromes: a large database study. Arthritis Rheumatol 2016; 67:3027-36. [PMID: 26245507 DOI: 10.1002/art.39292] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2014] [Accepted: 07/16/2015] [Indexed: 11/05/2022]
Abstract
OBJECTIVE To determine the type and frequency of musculoskeletal symptoms at onset and during followup of cryopyrin-associated periodic syndromes (CAPS). METHODS We retrospectively recorded the articular and muscular symptoms of patients with CAPS followed up in French hospitals. Data were presented as frequencies or the median (range), and patient groups were compared using chi-square test, Fisher's exact test, and Mann-Whitney test. RESULTS The study included 133 patients (33 children), 20 with familial cold autoinflammatory syndrome, 88 with Muckle-Wells syndrome, 22 with chronic infantile neurologic, cutaneous, articular syndrome, and 3 with unclassified CAPS. The median age was 35 years (range 0-78 years) at the time of the study, 1 year (range 0-41 years) at symptom onset, and 23 years (range 0-58 years) at diagnosis. The disease was sporadic in 17% of the patients. Cutaneous symptoms predominated at onset (77%), followed by articular symptoms (30%). The p.Thr348Met and p.Arg260Trp NLRP3 mutations were significantly associated with the presence and absence of articular symptoms at onset, respectively. During followup, 86% of the patients had musculoskeletal symptoms, 88% had arthralgia, and 58% had arthritis, but only 9% had joint destruction. Tendinopathies occurred in 21.5% of the patients, tender points in 16.5%, and myalgia in 33%. Only 3 patients had typical knee deformities. Radiographs were rarely obtained. Except for bone deformities, osteoarticular symptoms occurred at similar frequencies in the different CAPS phenotypes. CONCLUSION Joint manifestations were frequent in all CAPS phenotypes. Bone deformities were rare. Musculoskeletal manifestations varied within given families but tended to worsen over time.
Collapse
Affiliation(s)
| | - Eric Hachulla
- Nord-de-France University and Claude-Huriez University Hospital, Lille, France
| | | | - Pierre Quartier
- Necker-Enfants Malades University Hospital and Paris Descartes University, Paris, France
| | | | | | - Gilles Grateau
- Tenon University Hospital, AP-HP, and Paris VI Pierre et Marie Curie University, Paris, France
| | | | - Bénédicte Neven
- Necker-Enfants Malades University Hospital, AP-HP, and INSERM U768 Laboratory, Paris, France
| | | | | | - Pascal Pillet
- Pellegrin-Enfants University Hospital, Bordeaux, France
| | | | | | - Agnès Duquesne
- Women-Mothers-Children University Hospital, Lyon, France
| | | | | | - Jérome Stirnemann
- Jean Verdier University Hospital, AP-HP, Paris XIII University, Paris, France
| | | | | | | | | | | | | | | | - Pierre Duffau
- Saint André Hospital, and Bordeaux University Hospital, Bordeaux, France
| | - Amar Smail
- North University Hospital, Amiens, France
| | | | | | | | | | | | | | | | - Laurence Cuisset
- Cochin Institute and University Hospital, AP-HP, Paris Descartes University, Paris, France
| | | |
Collapse
|
50
|
Hebert V, Boulard C, Houivet E, Duvert Lehembre S, Borradori L, Della Torre R, Feliciani C, Fania L, Zambruno G, Camaioni D, Didona B, Marinovic B, Schmidt E, Schumacher N, Hünefeld C, Schanz S, Johannes Steffen Kern J, Hofmann S, Bouyeure A, Picard-Dahan C, Prost-Squarcioni C, Caux F, Alexandre M, Ingen-Housz-Oro S, Bagot M, Tancrede-Bohin E, Bouaziz J, Franck N, Vabres P, Labeille B, Aleth Richard M, Delaporte E, Dupuy A, D’Incan M, Quereux G, Skowron F, Paul C, Bulai Livideanu C, Beylot-Barry M, Doutre M, Avenel-Audran M, Bedane C, Bernard P, Machet L, Maillard H, Jullien D, Debarbieux S, Sassolas B, Misery L, Abasq C, Dereure O, Lagoutte P, Ferranti V, Werth V, Murrell D, Hertl M, Benichou J, Joly P. Reproductibilité inter-observateur des scores de sévérité du pemphigus ABSIS et PDAI. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|